Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Delayed onset bleomycin-induced pneumonitis.

I Uzel¹, M Ozguroglu, B Uzel

¹Department of Pulmonary Diseases, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.

|July 5, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ANALYSIS OF SHORT-CHAIN FATTY ACIDS AND ASSOCIATION WITH GLUCAGON-LIKE PEPTIDE-1 IN HEALTHY, OBESE, PREDIABETES AND TYPE 2 DIABETES INDIVIDUALS.

Acta endocrinologica (Bucharest, Romania : 2005)·2026

Same author

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function.

Actas urologicas espanolas·2024

Same author

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Same author

Different Clinical Effects of Ectodermal Dysplasias in Four Generations.

Actas dermo-sifiliograficas·2023

This study reports a rare case of bleomycin-induced pneumonitis occurring two years after chemotherapy for testicular cancer. This finding highlights the potential for delayed pulmonary toxicity from bleomycin treatment.

Area of Science:

Oncology
Pulmonology
Toxicology

Background:

Bleomycin is a chemotherapy agent used for testicular cancer.
Bleomycin can cause fatal pulmonary toxicity, including pneumonitis.
Pulmonary toxicity typically manifests during or shortly after bleomycin administration.

Observation:

A 39-year-old male developed bleomycin-induced pneumonitis.
The patient had completed chemotherapy for nonseminomatous testicular cancer.
Pneumonitis symptoms appeared two years after the completion of bleomycin therapy.

Findings:

This case represents a delayed onset of bleomycin-induced pneumonitis.
The typical timeframe for bleomycin pulmonary toxicity is within 6 months post-treatment.

Related Experiment Videos

This patient's presentation extends the known latency period for this adverse effect.

Implications:

Clinicians should consider the possibility of delayed bleomycin-induced pneumonitis.
Extended monitoring for pulmonary complications may be warranted in patients treated with bleomycin.
Further research is needed to understand the mechanisms of delayed bleomycin pulmonary toxicity.